Evaluation of Self-Care Activities and Quality of Life in Patients With Type 2 Diabetes Mellitus Treated With Metformin Using the 2D Matrix Code of Outer Drug Packages as Patient Identifier: Protocol for the DePRO Proof-of-Concept Observational Study

Christian Mueller, Isabel Schauerte, Stephan Martin, Christian Mueller, Isabel Schauerte, Stephan Martin

Abstract

Background: Diabetes mellitus (DM) is one of the most common noncommunicable diseases. DM has a substantial negative impact on patients' quality of life, which is measured using a variety of diabetes-specific measures covering multiple aspects of patients' psychological state, behavior, and treatment satisfaction. A fully digital data collection system, including patient identification, would represent a substantial advance in how these patient-reported outcome (PRO) data are measured. Within the European Union, one way to identify patients without the involvement of health care professionals is to use the unique 2D matrix codes on the packaging of prescription medication-for example, metformin, the recommended initial treatment for patients with type 2 DM (T2DM).

Objective: In the DePRO study we aim to (1) describe the self-care activities of patients with T2DM using metformin-containing medication; (2) describe the self-reported health status (eg, presence of diabetes complications and quality of life) of these patients; (3) describe associations between self-care activities and demographics and disease characteristics; and (4) assess the usability of the my ePRO app.

Methods: DePRO is an observational, multicenter, cross-sectional, digital, patient-driven study conducted in Germany. Patients with a prescription for a metformin-containing medication will be given a postcard by their pharmacist, which will include a download link for the my ePRO app. In total, 12 diabetes-focused pharmacies, selected to represent urban and rural areas, will be recruited. Participants will use their own mobile device (bring your own device) to download the my ePRO app and access the DePRO study, for which they can register using the 2D matrix code on their medication. An electronic informed consent form will be displayed to the patients and only after giving consent will patients be able to complete the study questionnaires. The PRO instruments used in the study are the Summary of Diabetes Self-Care Activities Scale, the Diabetes Treatment Satisfaction Questionnaire, and the 5 level, 5-dimension EuroQol Questionnaire. Patients will also be asked to complete a questionnaire with items addressing demographics, patient characteristics, disease history, complications, and concomitant medications. Data will be transferred to the study database by the app upon completion of each questionnaire. Statistical analyses of primary and secondary endpoints will be exploratory and descriptive.

Results: Enrollment began in June 2020. The estimated study completion date is December 31, 2020, and the planned sample size is 300 patients.

Conclusions: The DePRO study uses completely digital data collection, including authentication of eligible patients and completion of the study questionnaires. Therefore, the design of the DePRO study represents a substantial advance in the evaluation of the digital capturing of PRO data.

Trial registration: ClinicalTrials.gov NCT04383041; https://ichgcp.net/clinical-trials-registry/NCT04383041.

International registered report identifier (irrid): PRR1-10.2196/21727.

Keywords: bring your own device; digital observational study; patient-reported outcome measures; quality of life; self-care activities; type 2 diabetes mellitus.

Conflict of interest statement

Conflicts of Interest: CM is an employee of Bayer Vital GmbH (Leverkusen, Germany). IS is the COO of Institut Dr. Schauerte. SM has received support from Bayer Vital GmbH.

©Christian Mueller, Isabel Schauerte, Stephan Martin. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 11.01.2021.

Figures

Figure 1
Figure 1
Recruitment and data capturing process with the my ePRO app. EQ-5D-5L: 5-level, 5-dimension EuroQol Questionnaire; PIIC: patient information and informed consent form; PRO: patient-reported outcome.

References

    1. World Health Organization . Global Report on Diabetes. Geneva, Switzerland: World Health Organization; 2016. [2021-01-05]. .
    1. International Diabetes Federation IDF Diabetes Atlas, 9th Edition: Global Fact Sheet. 2019. [2021-01-05]. .
    1. Foundation of European Nurses in Diabetes Policy puzzle: the state we are in. Diabetes in Europe. [2021-01-05]. .
    1. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovič L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015 Apr;21 Suppl 1:1–87. doi: 10.4158/.
    1. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010 Oct 22;8:29. doi: 10.1186/1478-7954-8-29.
    1. Saleh F, Mumu SJ, Ara F, Hafez MA, Ali L. BMC Public Health. 2014 May 07;14:431. doi: 10.1186/1471-2458-14-431.
    1. Sun W, Aodeng S, Tanimoto Y, Watanabe M, Han J, Wang B, Yu L, Kono K. Quality of life (QOL) of the community-dwelling elderly and associated factors: a population-based study in urban areas of China. Arch Gerontol Geriatr. 2015;60(2):311–6. doi: 10.1016/j.archger.2014.12.002.
    1. da RFJ, Ogurtsova K, Linnenkamp U, Guariguata L, Seuring T, Zhang P, Cavan D, Makaroff LE. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res Clin Pract. 2016 Jul;117:48–54. doi: 10.1016/j.diabres.2016.04.016.
    1. American DA. Standards of Medical Care in Diabetes-2016 Abridged for Primary Care Providers. Clin Diabetes. 2016 Jan;34(1):3–21. doi: 10.2337/diaclin.34.1.3.
    1. Powers MA, Bardsley J, Cypress M, Duker P, Funnell MM, Fischl AH, Maryniuk MD, Siminerio L, Vivian E. Diabetes Self-Management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. J Acad Nutr Diet. 2015 Aug;115(8):1323–34. doi: 10.1016/j.jand.2015.05.012.
    1. Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. Diabetes Care. 2000 Jul;23(7):943–50.
    1. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med. 1990 Jun;7(5):445–51. doi: 10.1111/j.1464-5491.1990.tb01421.x.
    1. Tönnies T, Röckl S, Hoyer A, Heidemann C, Baumert J, Du Y, Scheidt-Nave C, Brinks R. Projected number of people with diagnosed Type 2 diabetes in Germany in 2040. Diabet Med. 2019 Oct;36(10):1217–1225. doi: 10.1111/dme.13902.
    1. Bloomgarden ZT, Handelsman Y. Approaches to treatment 2: Comparison of American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) type 2 diabetes treatment guidelines. J Diabetes. 2016 Jan;8(1):4–6. doi: 10.1111/1753-0407.12345.
    1. Schwabe U, Paffrath D, Ludwig W, Klauber J. Arzneiverordnungs-Report 2019. Berlin/Heidelberg, Germany: Springer-Verlag; 2019.
    1. The European Parliament and the Council of the European Union Directive 2011/62/EU of the European Parliament and of the Council. 2011. [2021-01-05]. .
    1. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011 Dec;20(10):1727–36. doi: 10.1007/s11136-011-9903-x.
    1. Ausili D, Bezze S, Canizzaro C, Bulgheroni M, Toolbert DJ, Genovese S, Di Mauro S. [Self-care assessment in type-2 diabetes: the Italian translation and validation of the Summary of Diabetes Self-Care Activities] Prof Inferm. 2015;68(1):9–18. doi: 10.7429/pi.2015.681009.
    1. Klein K, Stolk P. Challenges and Opportunities for the Traceability of (Biological) Medicinal Products. Drug Saf. 2018 Oct;41(10):911–918. doi: 10.1007/s40264-018-0678-7.
    1. The European Commission 2016. ommission Delegated Regulation (EU) 2016/161 of 2 October 2015 supplementing Directive 2001/83/EC of the European Parliament and of the Council by laying down detailed rules for the safety features appearing on the packaging of medicinal products for human use. 2016. [2021-01-05]. .
    1. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, Balasubramanian V, Russo AM, Rajmane A, Cheung L, Hung G, Lee J, Kowey P, Talati N, Nag D, Gummidipundi SE, Beatty A, Hills MT, Desai S, Granger CB, Desai M, Turakhia MP, Apple Heart Study Investigators Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med. 2019 Nov 14;381(20):1909–1917. doi: 10.1056/NEJMoa1901183.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe